Q-omics provides the consensus-scored RPS27AP17 profile across patient tissues and cancer cell-line models. RPS27AP17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPS27AP17 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPS27AP17 RNA expression shows 5,899 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, KIRC, and STAD as cancer lineages where RPS27AP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27AP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27AP17 survival associations across molecular data types. RPS27AP17 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27AP17 RNA expression–survival associations across cancer types. High RPS27AP17 expression shows unfavorable associations in CHOL, MESO, LUAD and ACC, but favorable associations in SKCM and ESCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for RPS27AP17 RNA expression.
This table summarizes RPS27AP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS27AP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27AP17 shows lower tumor expression in READ and THCA and higher tumor expression in KIRC, BRCA, LIHC and KIRP. The KIRC box plot shows higher RPS27AP17 RNA expression in tumor versus normal tissue (log2 FC = +0.545, t-test p < 0.001).
This table shows molecular features associated with RPS27AP17 in patient tissues and cancer cell lines. In patient samples, RPS27AP17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
